AI Insight
This study examined over 800 clinical Klebsiella pneumoniae isolates collected between 1997-2020 and found that 17.6% of carbapenem-susceptible bacteria displayed hidden antibiotic tolerance, meaning they could survive drug exposure despite appearing susceptible in standard tests. This pre-existing tolerance was associated with subsequent emergence of carbapenem resistance and facilitated the acquisition and maintenance of resistance-conferring plasmids. The researchers identified the uhpABC regulatory operon as a genetic factor linked to tolerance and demonstrated that tolerant bacteria evolved resistance to additional antibiotics more rapidly.
Why it matters
Standard susceptibility tests may miss tolerance that predisposes bacteria to developing full antibiotic resistance, potentially explaining why some infections fail treatment despite appearing treatable. Understanding tolerance mechanisms could help predict which bacterial populations are at higher risk for resistance evolution and inform strategies to prevent the spread of carbapenem-resistant infections in healthcare settings.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Antibiotic tolerance enables bacteria to survive bactericidal antibiotic exposure and has been linked to resistance evolution in laboratory systems and individual infections, but its role in plasmid-mediated resistance evolution in clinical populations remains unclear. Here, we analyzed a longitudinal collection of more than 800 clinical Klebsiella pneumoniae isolates spanning 1997-2020. Among 779 minimum inhibitory concentration (MIC)-defined ertapenem-susceptible isolates, 137 (17.6%) displayed hidden ertapenem tolerance, defined by enhanced survival after 6 h at 30 times the isolate-specific ertapenem MIC, mostly without extended lag time or reduced growth rate. Tolerance was detected before local ertapenem introduction and was enriched among ertapenem-resistant isolates, supporting a population-level association between pre-existing tolerance and the emergence of carbapenem resistance. Genomic and plasmid-curing analyses separated plasmid-mediated carbapenem resistance from plasmid-independent antibiotic tolerance. Moreover, tolerant recipient backgrounds enhanced resistance plasmid acquisition, preserved viable recipients following antibiotic exposure and accelerated ceftazidime-avibactam resistance evolution. A phylogeny-guided variant-enrichment analysis further identified the uhpABC regulatory operon as a candidate tolerance-associated locus, and coordinated expression of the complete operon increased ertapenem survival. Together, these findings identify clinical antibiotic tolerance as a pre-existing, MIC-hidden phenotype that can facilitate plasmid-mediated carbapenem resistance evolution in K. pneumoniae.